Ocrelizumab (Ocrevus) for people with relapsing-remitting multiple sclerosis
In 2018, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of Ocrelizumab (trade name: Ocrevus) compared with the standard treatments for people with relapsing-remitting multiple sclerosis (RRMS).
For this assessment, the manufacturer provided two studies involving a total of 1,377 people. Half of the participants had treatment with interferon beta, while the rest used ocrelizumab. The patients had an average of 2 flare-ups during the two years prior to the beginning of the study. The following results were found after about three years and eight months: